Beyond Tumor Size, Toward Meaningful Patient Outcomes

Дата публикации: 08-10-2026 00:00:00

This Viewpoint evaluates the present relevance of Response Evaluation Criteria in Solid Tumors (RECIST) as cancer therapeutics have evolved beyond cytotoxic chemotherapy in assessing treatment outcomes.

Схожие новости

#	Наименование новости	Тональность	Информативность	Дата публикации
1	Rethinking Treatment Intensification in Poorly Chemosensitive Ovarian Cancer	0	9.84	01-10-2026
2	Rethinking Value in Cancer Care in the US	0	5.62	01-10-2026
3	Circulating Tumor DNA Status and Adjuvant Chemotherapy in Resected Colorectal Liver Metastases	0	7	03-07-2026
4	Liquid Biopsies for Cancer	0	8.31	10-08-2026
5	Circulating Tumor DNA in Early Breast Cancer	0	9.02	01-07-2026
6	Checkpoint Inhibitors Plus Stereotactic Body Radiotherapy in Patients With Advanced Solid Tumors	0	4.57	01-09-2023
7	Omission of Axillary Dissection Following Nodal Downstaging With Neoadjuvant Chemotherapy	0	11.16	01-06-2024
8	Pembrolizumab Plus Chemotherapy for Cervical Cancer	0	14.76	10-09-2026
9	When TNM Staging Is Not Sufficient	0	9.11	30-07-2026
10	Management of Soft Tissue and Visceral Leiomyosarcomas	0	7.48	10-09-2026

Классификация: Пресс-релизы. Схожих патентов: 0. Схожих новостей: 10. Тональность: 0. Информативность: 8.26. Источник: jamanetwork.com.